SCHEMBL15061348

SCHEMBL15061348

COc1ccc2nc3cc(Cl)ccc3c(NCCCN(C)C)c2c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.72
KMT2A Q03164 5/20 0.70
MEN1 O00255 4/20 0.70
TDP1 Q9NUW8 2/20 0.70
MBNL1 Q9NR56 1/20 0.69
GSR P00390 7/20 0.61
USP2 O75604 4/20 0.59
TP53 P04637 3/20 0.59
CYP3A4 P08684 3/20 0.59
CASP1 P29466 3/20 0.59
CASP7 P55210 3/20 0.59
HBB P68871 3/20 0.59
HSD17B10 Q99714 3/20 0.59
CYP1A2 P05177 3/20 0.59
TSHR P16473 3/20 0.59
CYP2D6 P10635 2/20 0.59
BRCA1 P38398 2/20 0.59
HIF1A Q16665 2/20 0.59
NPC1 O15118 2/20 0.59
RAB9A P51151 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1153515 0.97 MBNL1 (0.71) ADORA2AKMT2AMEN1TDP1MBNL1
SCHEMBL18163879 0.93 ADORA2A (0.72) ADORA2AKMT2AMEN1TDP1MBNL1
SCHEMBL18163843 0.91 MBNL1 (0.70) ADORA2AKMT2AMEN1TDP1MBNL1
SCHEMBL7869225 0.91 MBNL1 (0.81) ADORA2AKMT2AMEN1TDP1MBNL1
SCHEMBL7880398 0.91 MEN1 (0.79) ADORA2AKMT2AMEN1TDP1MBNL1
SCHEMBL20091298 0.90 MBNL1 (0.71) ADORA2AKMT2AMEN1TDP1MBNL1
SCHEMBL18163845 0.90 ADORA2A (0.70) ADORA2AKMT2AMEN1TDP1MBNL1
SCHEMBL20087027 0.90 MBNL1 (0.80) ADORA2AKMT2AMEN1TDP1MBNL1
SCHEMBL20087077 0.90 MBNL1 (0.80) ADORA2AKMT2AMEN1TDP1MBNL1
SCHEMBL20087053 0.90 MBNL1 (0.80) ADORA2AKMT2AMEN1TDP1MBNL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130289024-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND 2013-10-31 US disclosed
US-8475804-B2 Compositions and methods for treatment of filovirus-mediated diseases U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) 2013-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130289024-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES FLNA, FLNB, PIGS ADORA2A 3597/4885KMT2A 3886/4885MEN1 3612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.